RETA Stock News

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?

New York, New York--(Newsfile Corp. - August 17, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such i

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such investors are

Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.

The stock price of Reata Pharmaceuticals, Inc. (Nasdaq: RETA) fell by over 10% pre-market. This is why it happened.

Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q2 2021 Results - Earnings Call Transcript

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 6.10% and 53.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the sto

Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 7.32% over the past year to ($1.3

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial

Reata Pharmaceuticals, Inc. (RETA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher i

Reata Pharmaceuticals has enjoyed robust appreciation over the years, as the company advances two lead medicines (bardoxolone and omaveloxolone).

PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced th

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA fi

The company might soon be taking a very big step toward FDA approval of an important pipeline drug.

The U.S. Food and Drug Administration (FDA) sent a communication to Reata Pharmaceuticals Inc. (NASDAQ: RETA) on Wednesday, recommending that it submits a new request for a pre-NDA meeting. The pharma